摘要
目的观察研究参麦注射液与环磷腺苷葡胺联合治疗老年肺心病伴心力衰竭的临床治疗效果。方法该院2009年11月—2011年12月共收治老年肺心病伴心力衰竭患者68例,随机将收治的患者分为两组治疗组(34例)和对照组(34例),对对照组34例患者采取常规治疗方式进行治疗,治疗组34例在常规治疗的基础之上加参麦注射液与心先安联合治疗,观察两组患者治疗效果。结果治疗组患者用药有效率(94.12%)明显高于对照患者用药有效率(70.59%),两组组间P<0.01有极显著差异,且两组患者用药前后分别检测血、尿、便,以及肝肾功能均未出现异常,未发现用药导致患者出现任何不良反应。结论参麦注射液与心先安联合治疗老年肺心病伴心力衰竭,两药能够发挥出不同的作用机制,协同作用于老年肺心病伴心力衰竭患者,且尚未发现不良反应,可对老年肺心病伴心力衰竭患者起到有效的治疗作用,值得临床广为推广。
To observe and study shenmai Injection and Meglumine Adenosine Cyclophosphate combined treatment of senile pulmonary heart disease with heart failure of clinical therapeutic effect. Methods From November 2009 - December 2011 were a total of elderly pulmonary heart disease with heart failure patients, 68 cases of patients were randomly divided into two groups treatment group (34 cases) and control group (34 eases), the control group 34 patients take routine treatment, the treatment group 34 cases in the conventional treatment on the basis of shenmai injection and heart with first Ann combined treatment. Then we observated two groups of patients treatment effect. Results The treatment group patients have effective rate (94.12%) in the patients with evidently higher than those of control drug effective rate (70.59%), the P 〈 0.01, it has a very significant difference, and the two groups of patients were measured blood, urine, as well as lier and renal function, they were normal, without finding drug predispose patients to any adverse reaction. Conclusion Shenmai injection and heart first Ann combined treatment of senile pulmonary heart disease with heart failure are able to show the different mechanism of action, synergy in old age with heart failure patients, and the treatment have not yet found adverse reaction, the elderly pulmonary heart disease with heart failure patients with an effective therapy effect, it is worth promoting in clinical area widely.
出处
《中国卫生产业》
2013年第1期26-27,共2页
China Health Industry
关键词
参麦注射液
环磷腺苷葡胺
老年肺心病
心力衰竭
Shenmai injection
Meglumine Adenosine Cyclophosphate
Elderly pulmonary heart disease
Heart failure